▟ Vinebot intrinsic value, daily

← back

DOC Healthpeak Properties

reit · valued with opus medium conviction · deep-dived 2026-10-12

STRONG BUY
Intrinsic value$21.75
Price (at call)$18.80
Margin of safety +15.7%
vs market (rating basis) +82.5%

Outpatient medical annuity at a ~7.8% AFFO yield; lab glut and rates explain the discount, not justify it.

The story

Healthpeak owns a roughly $20B+ portfolio split across outpatient medical (the largest, steadiest segment after the Physicians Realty merger), lab/life science concentrated in South San Francisco, Boston and San Diego, and CCRC/senior housing. Outpatient medical demand rides aging demographics and the shift of care to outpatient settings, while lab faces a supply glut and weak biotech funding that keeps occupancy and re-leasing spreads under pressure. The balance sheet is investment grade (BBB+) at about 5.2x net debt/EBITDA with mostly fixed-rate debt. Even so, the stock trades like a long-duration bond and reprices with the 10-year. FFO of about $1.88/share on a $18.80 price is roughly a 10x multiple and a ~7.8% AFFO yield.

I trimmed Y1 growth from 4% to 3% because the 10% price drop since August, flat recent FFO guidance and continued lab leasing weakness suggest same-store growth in outpatient medical (about 3%) is being offset by lab occupancy drag; nothing structural changed, so the other drivers stay. AFFO/FFO stays at 0.78 because lab TI/leasing costs and medical office capex are heavy. Beta of 0.92 and 3% failure risk reflect an investment-grade, diversified healthcare landlord with real rate sensitivity. The baseline's $32 overstates value because it ignores the recurring capex haircut; on AFFO my value lands in the low-to-mid $20s, a 20-30% gap to market that the lab overhang explains.

Value drivers

AFFO growth (Y1)3.0%
Terminal AFFO growth2.5%
AFFO / FFO ratio78.0%
Beta0.92
Failure probability3.0%
Cost of equity9.4%

Valuation bridge

PV of AFFO (explicit)7.36B
PV of terminal value8.10B
Equity value15.00B
÷ shares → per share$21.75

Projected AFFO

YrFFOAFFOGrowthPV
11.34B 1.05B3.0% 957.81M
21.38B 1.08B2.9% 901.43M
31.42B 1.11B2.9% 847.90M
41.46B 1.14B2.8% 797.12M
51.50B 1.17B2.8% 748.98M
61.54B 1.20B2.7% 703.37M
71.59B 1.24B2.7% 660.17M
81.63B 1.27B2.6% 619.29M
91.67B 1.30B2.6% 580.63M
101.71B 1.33B2.5% 544.09M

Key risks

  • Lab oversupply and weak biotech funding push occupancy and rents down longer than expected
  • Higher-for-longer rates compress REIT multiples and raise refinancing costs on 2027-2028 maturities
  • Tenant credit stress among small-cap biotechs and health-system operators, plus CCRC operating volatility

Catalysts

  • Lab leasing inflection and stabilization of South San Francisco occupancy as biotech funding recovers
  • Fed cuts lowering the 10-year, plus buybacks or accretive outpatient medical development deliveries

History

DatePriceIntrinsicMoSRating
2026-10-12$18.80 $21.75 +15.7% STRONG BUY
2026-08-31$20.96 $24.55 +17.1% STRONG BUY
2026-07-07$21.75 $24.82 +14.1% STRONG BUY
2026-06-23$20.56 $24.86 +20.9% STRONG BUY